CHC LABS INC.
|
DIGOXIN THERAPEUTIC DRUG ASSAY (80162) |
|
|
242.00-242.91 |
Toxic diffuse goiter without thyrotoxic crisis or storm |
|
243 |
Congenital hypothyroidism |
|
244.0-244.9 |
Postsurgical hypothyroidism |
|
245.0-245.9 |
Acute thyroiditis |
|
275.2 |
Disorders of magnesium metabolism |
|
275.40-275.49 |
Unspecified disorder of calcium metabolism |
|
276.0 |
Hyperosmolality and/or hypernatremia |
|
276.1 |
Hyposmolality and/or hyponatremia |
|
276.2 |
Acidosis |
|
276.3 |
Alkalosis |
|
276.4 |
Mixed acid-base balance disorder |
|
276.50 |
Volume depletion, unspecified |
|
276.51 |
Dehydration |
|
276.52 |
Hypovolemia |
|
276.6 |
Fluid overload disorder |
|
276.7 |
Hyperpotassemia |
|
276.8 |
Hypopotassemia |
|
276.9 |
Electrolyte and fluid disorders not elsewhere classified |
|
293.0 |
Acute delirium |
|
293.1 |
Subacute delirium |
|
307.47 |
Other dysfunctions of sleep stages or arousal from sleep |
|
368.16 |
Psychophysical visual disturbances |
|
368.8 |
Other specified visual disturbance |
|
368.9 |
Unspecified visual disturbance |
|
397.9 |
Rheumatic diseases of endocardium valve unspecified |
|
398.0 |
Rheumatic myocarditis |
|
398.91 |
Rheumatic heart failure (congestive) |
|
402.01 |
Malignant hypertensive heart disease with heart failure |
|
402.11 |
Benign hypertensive heart disease with heart failure |
|
402.91 |
Unspecified hypertensive heart disease with heart failure |
|
403.00-403.91 |
Malignant hypertensive renal disease without renal failure |
|
404.00-404.93 |
Malignant hypertensive heart and renal disease without heart failure or renal failure |
|
410.00-410.92 |
Acute myocardial infarction of anterolateral wall episode of care unspecified |
|
411.0-411.89 |
Postmyocardial infarction syndrome |
|
413.0-413.9 |
Angina decubitus |
|
422.0-422.99 |
Acute myocarditis in diseases classified elsewhere |
|
425.0-425.9 |
Endomyocardial fibrosis |
|
426.0-426.9 |
Atrioventricular block complete |
|
427.0-427.9 |
Paroxysmal supraventricular tachycardia |
|
428.0-428.9 |
Congestive heart failure unspecified |
|
429.2 |
Cardiovascular disease unspecified |
|
429.4 |
Functional disturbances following cardiac surgery |
|
429.5 |
Rupture of chordae tendineae |
|
429.6 |
Rupture of papillary muscle |
|
429.71 |
Certain sequelae of myocardial infarction not elsewhere classified acquired cardiac septal defect |
|
514 |
Pulmonary congestion and hypostasis |
|
579.9 |
Unspecified intestinal malabsorption |
|
584.5-584.9 |
Acute renal failure with lesion of tubular necrosis |
|
585.1 |
Chronic kidney disease, Stage I |
|
585.2 |
Chronic kidney disease, Stage II (mild) |
|
585.3 |
Chronic kidney disease, Stage III (moderate) |
|
585.4 |
Chronic kidney disease, Stage IV (severe) |
|
585.5 |
Chronic kidney disease, Stage V ( |
|
585.6 |
End stage renal disease |
|
585.9 |
Chronic kidney disease, unspecified |
|
586 |
Renal failure unspecified |
|
587 |
Renal sclerosis unspecified |
|
588.0 |
Renal osteodystrophy |
|
588.1 |
Nephrogenic diabetes insipidus |
|
588.81 |
Secondary hyperparathyroidism (of renal origin) |
|
588.89 |
Other specified disorders resulting from impaired renal function |
|
588.9 |
Unspecified disorder resulting from impaired renal function |
|
780.01 |
Coma |
|
780.02 |
Transient alteration of awareness |
|
780.09 |
Alteration of consciousness other |
|
780.1 |
Hallucinations |
|
780.2 |
Syncope and collapse |
|
780.4 |
Dizziness and giddiness |
|
780.71-780.79 |
Chronic fatigue syndrome |
|
783.0 |
Anorexia |
|
784.0 |
Headache |
|
787.01-787.03 |
Nausea with vomiting |
|
787.91 |
Diarrhea |
|
794.31 |
Nonspecific abnormal electrocardiogram (ECG) (EKG) |
|
799.2 |
Nervousness |
|
972.0 |
Poisoning by cardiac rhythm regulators |
|
972.1 |
Poisoning by cardiotonic glycosides and drugs of similar action |
|
995.2 |
Unspecified adverse effect of drug medicinal and biological substance not elsewhere classified |
|
E942.1 |
Cardiotonic glycosides and drugs of similar action causing adverse effects in therapeutic use |
|
V58.69 |
Long-term (current) use of other medications (digoxin) |
This policy has been duplicated from the most current Medicare National Coverage Determination or Local Medical Review Policy available at the time this booklet was printed in October 2005. Medicare will consider this test(s) medically reasonable and necessary only if the test(s) was performed for any of the diagnoses/conditions listed on this page. This information is subject to change without notice, and Covenant Health Care Labs (CHC) is not responsible for consequences that may result from using such information. CHC is not indicating one code is more acceptable than another, and that selected codes should reflect the patients actual medical condition as noted in their medical record.
|